Repeatability of Deuterium Metabolic Imaging of Healthy Volunteers at 3 T

Overview

Journal Eur Radiol Exp

Date 2024 Mar 13

PMID 38472611

Authors

Nikolaj Bogh

Michael Vaeggemose

Rolf F Schulte

Esben S S Hansen

Christoffer Laustsen

Affiliations

Soon will be listed here.

Abstract

Background: Magnetic resonance (MR) imaging of deuterated glucose, termed deuterium metabolic imaging (DMI), is emerging as a biomarker of pathway-specific glucose metabolism in tumors. DMI is being studied as a useful marker of treatment response in a scan-rescan scenario. This study aims to evaluate the repeatability of brain DMI.

Methods: A repeatability study was performed in healthy volunteers from December 2022 to March 2023. The participants consumed 75 g of [6,6'-H]glucose. The delivery of H-glucose to the brain and its conversion to H-glutamine + glutamate, H-lactate, and H-water DMI was imaged at baseline and at 30, 70, and 120 min. DMI was performed using MR spectroscopic imaging on a 3-T system equipped with a H/H-tuned head coil. Coefficients of variation (CoV) were computed for estimation of repeatability and between-subject variability. In a set of exploratory analyses, the variability effects of region, processing, and normalization were estimated.

Results: Six male participants were recruited, aged 34 ± 6.5 years (mean ± standard deviation). There was 42 ± 2.7 days between sessions. Whole-brain levels of glutamine + glutamate, lactate, and glucose increased to 3.22 ± 0.4 mM, 1.55 ± 0.3 mM, and 3 ± 0.7 mM, respectively. The best signal-to-noise ratio and repeatability was obtained at the 120-min timepoint. Here, the within-subject whole-brain CoVs were -10% for all metabolites, while the between-subject CoVs were -20%.

Conclusions: DMI of glucose and its downstream metabolites is feasible and repeatable on a clinical 3 T system.

Trial Registration: ClinicalTrials.gov, NCT05402566 , registered the 25th of May 2022.

Relevance Statement: Brain deuterium metabolic imaging of healthy volunteers is repeatable and feasible at clinical field strengths, enabling the study of shifts in tumor metabolism associated with treatment response.

Key Points: • Deuterium metabolic imaging is an emerging tumor biomarker with unknown repeatability. • The repeatability of deuterium metabolic imaging is on par with FDG-PET. • The study of deuterium metabolic imaging in clinical populations is feasible.

Citing Articles

PyAMARES, an Open-Source Python Library for Fitting Magnetic Resonance Spectroscopy Data.

Xu J, Vaeggemose M, Schulte R, Yang B, Lee C, Laustsen C Diagnostics (Basel). 2024; 14(23).

PMID: 39682576 PMC: 11639817. DOI: 10.3390/diagnostics14232668.

Test-Retest Reproducibility of Reduced-Field-of-View Density-Weighted CRT MRSI at 3T.

Farley N, Susnjar A, Chiew M, Emir U Tomography. 2024; 10(4):493-503.

PMID: 38668396 PMC: 11055142. DOI: 10.3390/tomography10040038.

References

Simoes R, Henriques R, Cardoso B, Fernandes F, Carvalho T, Shemesh N . Glucose fluxes in glycolytic and oxidative pathways detected in vivo by deuterium magnetic resonance spectroscopy reflect proliferation in mouse glioblastoma. Neuroimage Clin. 2022; 33:102932. PMC: 8760481. DOI: 10.1016/j.nicl.2021.102932. View

Li C, Gore J, Davatzikos C . Multiplicative intrinsic component optimization (MICO) for MRI bias field estimation and tissue segmentation. Magn Reson Imaging. 2014; 32(7):913-23. PMC: 4401088. DOI: 10.1016/j.mri.2014.03.010. View

Hesse F, Wright A, Bulat F, Somai V, Kreis F, Brindle K . Deuterium MRSI of tumor cell death in vivo following oral delivery of H-labeled fumarate. Magn Reson Med. 2022; 88(5):2014-2020. PMC: 9545469. DOI: 10.1002/mrm.29379. View

De Feyter H, de Graaf R . Deuterium metabolic imaging - Back to the future. J Magn Reson. 2021; 326:106932. PMC: 8083995. DOI: 10.1016/j.jmr.2021.106932. View

Veraart J, Novikov D, Christiaens D, Ades-Aron B, Sijbers J, Fieremans E . Denoising of diffusion MRI using random matrix theory. Neuroimage. 2016; 142:394-406. PMC: 5159209. DOI: 10.1016/j.neuroimage.2016.08.016. View

Schulte R, Sacolick L, Deppe M, Janich M, Schwaiger M, Wild J . Transmit gain calibration for nonproton MR using the Bloch-Siegert shift. NMR Biomed. 2011; 24(9):1068-72. DOI: 10.1002/nbm.1657. View

De Feyter H, Behar K, Corbin Z, Fulbright R, Brown P, McIntyre S . Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo. Sci Adv. 2018; 4(8):eaat7314. PMC: 6105304. DOI: 10.1126/sciadv.aat7314. View

Magistretti P, Allaman I . Lactate in the brain: from metabolic end-product to signalling molecule. Nat Rev Neurosci. 2018; 19(4):235-249. DOI: 10.1038/nrn.2018.19. View

Taglang C, Batsios G, Mukherjee J, Tran M, Gillespie A, Hong D . Deuterium magnetic resonance spectroscopy enables noninvasive metabolic imaging of tumor burden and response to therapy in low-grade gliomas. Neuro Oncol. 2022; 24(7):1101-1112. PMC: 9248401. DOI: 10.1093/neuonc/noac022. View

10.

Lodge M . Repeatability of SUV in Oncologic F-FDG PET. J Nucl Med. 2017; 58(4):523-532. PMC: 5373499. DOI: 10.2967/jnumed.116.186353. View

11.

Batsios G, Taglang C, Tran M, Stevers N, Barger C, Gillespie A . Deuterium Metabolic Imaging Reports on TERT Expression and Early Response to Therapy in Cancer. Clin Cancer Res. 2022; 28(16):3526-3536. PMC: 9378519. DOI: 10.1158/1078-0432.CCR-21-4418. View

12.

Bednarik P, Goranovic D, Svatkova A, Niess F, Hingerl L, Strasser B . H magnetic resonance spectroscopic imaging of deuterated glucose and of neurotransmitter metabolism at 7 T in the human brain. Nat Biomed Eng. 2023; 7(8):1001-1013. PMC: 10861140. DOI: 10.1038/s41551-023-01035-z. View

13.

Froeling M, Prompers J, Klomp D, van der Velden T . PCA denoising and Wiener deconvolution of P 3D CSI data to enhance effective SNR and improve point spread function. Magn Reson Med. 2021; 85(6):2992-3009. PMC: 7986807. DOI: 10.1002/mrm.28654. View

14.

Martinez-Reyes I, Chandel N . Cancer metabolism: looking forward. Nat Rev Cancer. 2021; 21(10):669-680. DOI: 10.1038/s41568-021-00378-6. View

15.

Niess F, Hingerl L, Strasser B, Bednarik P, Goranovic D, Niess E . Noninvasive 3-Dimensional 1 H-Magnetic Resonance Spectroscopic Imaging of Human Brain Glucose and Neurotransmitter Metabolism Using Deuterium Labeling at 3T : Feasibility and Interscanner Reproducibility. Invest Radiol. 2023; 58(6):431-437. PMC: 10184811. DOI: 10.1097/RLI.0000000000000953. View

16.

Kaggie J, Khan A, Matys T, Schulte R, Locke M, Grimmer A . Deuterium metabolic imaging and hyperpolarized C-MRI of the normal human brain at clinical field strength reveals differential cerebral metabolism. Neuroimage. 2022; 257:119284. DOI: 10.1016/j.neuroimage.2022.119284. View

17.

Ruhm L, Avdievich N, Ziegs T, Nagel A, De Feyter H, de Graaf R . Deuterium metabolic imaging in the human brain at 9.4 Tesla with high spatial and temporal resolution. Neuroimage. 2021; 244:118639. PMC: 8591372. DOI: 10.1016/j.neuroimage.2021.118639. View

18.

Kreis F, Wright A, Hesse F, Fala M, Hu D, Brindle K . Measuring Tumor Glycolytic Flux in Vivo by Using Fast Deuterium MRI. Radiology. 2019; 294(2):289-296. DOI: 10.1148/radiol.2019191242. View

19.

Vanhamme , van den Boogaart A , Van Huffel S . Improved method for accurate and efficient quantification of MRS data with use of prior knowledge . J Magn Reson. 1998; 129(1):35-43. DOI: 10.1006/jmre.1997.1244. View

20.

Smith S, Jenkinson M, Woolrich M, Beckmann C, Behrens T, Johansen-Berg H . Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004; 23 Suppl 1:S208-19. DOI: 10.1016/j.neuroimage.2004.07.051. View